Gulf International Bank UK Ltd cut its holdings in Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,723 shares of the life sciences company’s stock after selling 175 shares during the period. Gulf International Bank UK Ltd’s holdings in Illumina were worth $12,783,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Strategy Asset Managers LLC purchased a new stake in shares of Illumina during the 1st quarter worth approximately $26,000. Massmutual Trust Co. FSB ADV grew its stake in shares of Illumina by 83.0% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the period. C J Advisory Inc acquired a new position in shares of Illumina during the 1st quarter worth $29,000. Lake Point Wealth Management purchased a new stake in shares of Illumina in the 4th quarter worth about $30,000. Finally, Valeo Financial Advisors LLC boosted its position in shares of Illumina by 130.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock worth $36,000 after buying an additional 65 shares in the last quarter. Institutional investors and hedge funds own 89.82% of the company’s stock.
Several equities analysts have recently commented on ILMN shares. OTR Global cut Illumina to a “positive” rating in a research note on Tuesday, April 2nd. Bank of America set a $80.00 target price on Colgate-Palmolive and gave the company a “buy” rating in a research note on Friday, July 12th. Zacks Investment Research cut GasLog Partners LP Unit from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 2nd. Wolfe Research assumed coverage on Waters in a research note on Thursday, May 30th. They set an “underperform” rating for the company. Finally, BidaskClub cut Weyco Group from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $338.69.
Shares of Illumina stock traded down $0.38 during trading on Wednesday, hitting $304.26. 18,597 shares of the stock traded hands, compared to its average volume of 1,524,312. The company has a market capitalization of $44.78 billion, a PE ratio of 53.22, a P/E/G ratio of 2.60 and a beta of 1.15. The company has a current ratio of 3.66, a quick ratio of 3.33 and a debt-to-equity ratio of 0.27. Illumina, Inc. has a twelve month low of $268.62 and a twelve month high of $380.76. The business’s fifty day moving average is $341.62.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business had revenue of $846.00 million during the quarter, compared to the consensus estimate of $838.70 million. During the same period last year, the company earned $1.45 earnings per share. Illumina’s quarterly revenue was up 8.2% on a year-over-year basis. As a group, analysts forecast that Illumina, Inc. will post 6.34 earnings per share for the current fiscal year.
In related news, insider Francis A. Desouza sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $310.01, for a total transaction of $930,030.00. Following the sale, the insider now owns 72,836 shares of the company’s stock, valued at approximately $22,579,888.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Charles Dadswell sold 124 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $311.77, for a total value of $38,659.48. Following the sale, the senior vice president now directly owns 8,086 shares in the company, valued at approximately $2,520,972.22. The disclosure for this sale can be found here. In the last quarter, insiders sold 65,991 shares of company stock worth $21,417,166. Corporate insiders own 0.38% of the company’s stock.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.